Radius Health Inc RDUS:NASDAQ

Last Price$29.02NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/16/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$28.20 (1)
Ask (Size)$29.69 (1)
Day Low / HighN/A - N/A
Volume727.4 K
 

View Biotechnology IndustryPeer Comparison as of 09/16/2019

 

Radius Health Inc ( NASDAQ )

Price: $29.02
Change: +0.68 (2.40%)
Volume: 727.4 K
4:00PM ET 9/16/2019
 
 

Fate Therapeutics Inc ( NASDAQ )

Price: $18.09
Change: +0.16 (0.89%)
Volume: 756.8 K
4:00PM ET 9/16/2019
 
 

Alector Inc ( NASDAQ )

Price: $19.37
Change: +0.38 (2.00%)
Volume: 389.4 K
4:00PM ET 9/16/2019
 
 

Sangamo Therapeutics Inc ( NASDAQ )

Price: $11.30
Change: +0.45 (4.15%)
Volume: 807.1 K
4:00PM ET 9/16/2019
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $69.89
Change: +1.92 (2.82%)
Volume: 117.6 K
4:00PM ET 9/16/2019
 

Read more news Recent News

Analyst Actions: Citigroup Upgrades Radius Health to Buy From Neutral, Lifts Price Target to $40 From $24
8:00AM ET 8/29/2019 MT Newswires

Radius Health's (RDUS) average rating among analysts is a buy, with an average price target of $38. Price: 25.95, Change: +1.05, Percent Change: +4.22 ...

Analyst Actions: Goldman Sachs Upgrades Radius Health to Buy From Neutral, Lifts PT to $38 From $26
9:57AM ET 5/29/2019 MT Newswires

Radius Health's (RDUS) average rating among analysts is a buy, with an average price target of $40. Price: 21.69, Change: +0.47, Percent Change: +2.19 ...

Insider Trends: 90-Day Insider Buying Trend at Radius Health Reduced with Sale of Shares
4:13PM ET 4/19/2019 MT Newswires

Kurt Graves, Director, reported a sale of 4,800 shares in Radius Health (RDUS) on Apr 16, 2019, for $107,136. Following the Form 4 filing with the SEC,...

Insider Trends: Radius Health Insider Sale Scales Back 90-Days of Buys
4:16PM ET 4/12/2019 MT Newswires

Dr Debasish Roychowdhury, Director, reported a sale of 4,800 shares in Radius Health (RDUS) on Apr 11, 2019, for $106,320. After the Form 4 filing with...

Company Profile

Business DescriptionRadius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA. View company web site for more details
Address950 Winter Street
Waltham, Massachusetts 02451
Phone+1.617.551.4000
Number of Employees398
Recent SEC Filing08/07/201910-Q
President, Chief Executive Officer& DirectorJesper Høiland
CFO, Treasurer, Principal Accounting Officer & SVPJose Carmona
Chief Medical OfficerCharles Q. Morris
Vice President-Technical OperationsChhaya Shah

Company Highlights

Price Open$28.25
Previous Close$29.02
52 Week Range$12.81 - 29.68
Market Capitalization$1.3 B
Shares Outstanding46.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/07/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.69
Beta vs. S&P 500N/A
Revenue$99.2 M
Net Profit Margin-127.22%
Return on Equity-368.58%

Analyst Ratings as of 08/30/2019

Buy
5
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset